Evidence map›Paper›PMID 31703585›Full record

ArticleMolecular neurodegeneration2019

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.

Mylene Huebecker, Elizabeth B Moloney, Aarnoud C van der Spoel, David A Priestman, Ole Isacson, Penelope J Hallett, Frances M Platt

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 166 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  5. Article
  6. Article
  7. Gangliosides in molecular interactions and cell regulation.The Journal of biological chemistry · 2026
    Review
  8. LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. A Common PD-RiskbioRxiv : the preprint server for biology · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Lack of significant ganglioside changes inBiochemistry and biophysics reports · 2025
    Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Mylene HuebeckerDepartment of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK.
Elizabeth B MoloneyNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, 02478, USA.
Aarnoud C van der SpoelDepartments of Pediatrics and Biochemistry & Molecular Biology, Atlantic Research Centre, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
David A PriestmanDepartment of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK.
Ole IsacsonNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, 02478, USA. isacson@hms.harvard.edu.
Penelope J HallettNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, 02478, USA. phallett@mclean.harvard.edu.
Frances M PlattDepartment of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK. frances.platt@pharm.ox.ac.uk.ORCID http://orcid.org/0000-0001-7614-0403
Harvard University · USUniversity of Oxford · GBDalhousie University · CA

Funding

Prevention of complement and immune-mediated Lewy body dementiaR01AG060195 · NIA · MCLEAN HOSPITAL · PI HALLETT, PENELOPE JANE, HASTINGS, MICHELLE L · 2018 to 2022
$2.9M
NIA NIH HHS R01 AG060195Wellcome Trust 202834/Z/16/Z
6 · The paper itself

Abstract

backgroundHaploinsufficiency in the Gaucher disease GBA gene, which encodes the lysosomal glucocerebrosidase GBA, and ageing represent major risk factors for developing Parkinson's disease (PD). Recently, more than fifty other lysosomal storage disorder gene variants have been identified in PD, implicating lysosomal dysfunction more broadly as a key risk factor for PD. Despite the evidence of multiple lysosomal genetic risks, it remains unclear how sphingolipid hydrolase activities, other than GBA, are altered with ageing or in PD. Moreover, it is not fully known if levels of glycosphingolipid substrates for these enzymes change in vulnerable brain regions of PD. Finally, little is known about the levels of complex gangliosides in substantia nigra which may play a significant role in ageing and PD.

methodsTo study sphingolipid hydrolase activities and glycosphingolipid expression in ageing and in PD, two independent cohorts of human substantia nigra tissues were obtained. Fluorescent 4-methylumbelliferone assays were used to determine multiple enzyme activities. The lysosomal GBA and non-lysosomal GBA2 activities were distinguished using the inhibitor NB-DGJ. Sensitive and quantitative normal-phase HPLC was performed to study glycosphingolipid levels. In addition, glycosphingolipid levels in cerebrospinal fluid and serum were analysed as possible biomarkers for PD.

resultsThe present study demonstrates, in two independent cohorts of human post-mortem substantia nigra, that sporadic PD is associated with deficiencies in multiple lysosomal hydrolases (e.g. α-galactosidase and β-hexosaminidase), in addition to reduced GBA and GBA2 activities and concomitant glycosphingolipid substrate accumulation. Furthermore, the data show significant reductions in levels of complex gangliosides (e.g. GM1a) in substantia nigra, CSF and serum in ageing, PD, and REM sleep behaviour disorder, which is a strong predictor of PD.

conclusionsThese findings conclusively demonstrate reductions in GBA activity in the parkinsonian midbrain, and for the first time, reductions in the activity of several other sphingolipid hydrolases. Furthermore, significant reductions were seen in complex gangliosides in PD and ageing. The diminished activities of these lysosomal hydrolases, the glycosphingolipid substrate accumulation, and the reduced levels of complex gangliosides are likely major contributors to the primary development of the pathology seen in PD and related disorders with age.

Indexed as

AgedAgingalpha-SynucleinFemaleGlucosylceramidaseHumansHydrolasesLysosomesMaleMutationParkinson DiseaseRisk FactorsSubstantia Nigraalpha-SynucleinGlucosylceramidaseHydrolasesAgeingGangliosideGlucocerebrosidaseGlycosphingolipidLysosomeNeurodegenerationParkinson’s disease

Identifiers

PMID31703585
PMCPMC6842240
OpenAlexW2973720548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.